Transgene S.A. Stock
Your prediction
Transgene S.A. Stock
There is an upward development for Transgene S.A. compared to yesterday, with an increase of €0.038 (2.690%).
So far the community has only identified positive things for Transgene S.A. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Transgene S.A. in the next few years
Pros
?
G***** c******* t* c**********
?
S********** s********
?
W********* I********* f** t** n*** y****
Cons
?
M***** P*******
?
B****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Transgene S.A. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Transgene S.A. | 2.690% | 11.692% | 31.047% | -26.888% | 8.358% | -44.580% | -49.671% |
| Valneva SE | -0.820% | -7.157% | 3.304% | -24.139% | -23.296% | -71.129% | 4.514% |
| Nanobiotix | -2.320% | -7.261% | -10.391% | 50.373% | -21.417% | -63.067% | -56.621% |
| Quantum Genomics S.A. | 0.400% | 7.265% | 7.725% | -17.298% | 14.091% | -97.715% | - |
Comments
News
Transgene Announces Upcoming Investor Meetings
Regulatory News:
TRANSGENE (Paris:TNG) today announces that Management will participate in several investor events in the upcoming investor events, as set out below.
Transgene will meet
Transgene Strengthens its Leadership Team to Accelerate its Growth Strategy
Regulatory News:
Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, is pleased to announce the
Transgene Reports Business Update and Q3 2023 Financial Position
Regulatory News:
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces its business update and its